,i #aadth ,,congress #ast ,session ,h4 ,r4 #bdee ,,in ,,the ,,house ,,of ,,representatives ,may #ai1 #bjae ,mr4 ,pitts introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act with respect to precision medicine4 #a4 ,precision medicine guidance and other programs of ,food and ,drug ,administration ,chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cea et seq47 is amended by adding at the end the following3 ,j ,precision ,medicine #eia4 ,general agency guidance on precision medicine 7a7 ,in general ,the ,secretary shall issue and periodically update guidance to assist sponsors in the development of a precision drug or biological product4 ,such guidance shall-- 7#a7 define the term precision drug or biological product2 and 7#b7 address the topics described in subsection 7b74 7b7 ,certain issues ,the topics to be addressed by guidance under subsection 7a7 are-- 7#a7 the evidence needed to support the use of biomarkers 7as defined in section #ejg7;e77 that identify subsets of patients as likely responders to therapies in order to streamline the conduct of clinical trials2 7#b7 recommendations for the design of studies to demonstrate the validity of a biomarker as a predictor of drug or biological product response2 7#c7 the manner and extent to which a benefit-risk assessment may be affected when clinical trials are limited to patient population subsets that are identified using biomarkers2 7#d7 the development of companion diagnostics in the context of a drug development program2 and 7#e7 considerations for developing biomarkers that aid prescribing decisions for a drug or biological product1 and when information regarding a biomarker may be included in the labeling for a drug or biological product approved under section #eje of this ,act or section #cea of the ,public ,health ,service ,act4 7c7 ,date certain for initial guidance ,the ,secretary shall issue guidance under subsection 7a7 not later than #ah months after the date of the enactment of the #bast ,century ,cures ,act4 #eib4 ,precision medicine regarding orphan-drug and expedited-approval programs ,in the case of an application for a precision drug or biological product under section #eje7;b77#a71 or section #cea7;a7 of the ,public ,health ,service ,act1 that has been designated under section #ebf as a drug for a rare disease for a serious condition1 the ,secretary may-- 7#a7 consistent with applicable standards for approval1 rely upon data or information previously developed by the sponsor of the precision drug or biological product for a prior approved drug or indication 7or that of another sponsor1 provided the sponsor of the precision drug or biological product has obtained a contractual right of reference to such other sponsor's data and information7 in order to expedite clinical development for a precision drug or indication that is using the same or similar approach as that of the prior approved drug or indication2 and 7#b7 as appropriate under section #ejf1 consider the application for approval of such precision drug or biological product to be eligible for expedited review1 including under section #ejf7;c7 7relating to accelerated approval74 4